Lynch Syndrome and Immunotherapy — A Family Question

Usually yes — but start with the limit, not the hope. Most people with a bowel or uterine cancer are not candidates. Checkpoint inhibitor immunotherapy is an evidence-based option only when the tumour tests MSI-High, also reported as dMMR. That is roughly 4 to 5 in every 100 advanced colorectal cancers. Lynch-related tumours nearly always sit inside that small group.

Across all stages of colorectal cancer taken together, about 15 in 100 tumours are MSI-High. Lynch syndrome itself is uncommon, accounting for roughly 3 in every 100 colorectal cancers and a broadly similar share of endometrial cancers. These ranges follow NCCN and ESMO patient guidance current as of August 2026.

Both sides of that matter. If a confirmed Lynch syndrome diagnosis sits behind your cancer, you are far more likely than average to be in the group for whom immunotherapy is considered. If it does not, the odds are that your tumour is MSS or pMMR, and chemotherapy, targeted therapy and clinical trials remain the established path.

And Lynch syndrome is the one situation in cancer care where your test result is not only about you. It changes what your parents, brothers, sisters and children should be doing about screening — whether or not you ever receive a single dose of immunotherapy.

Eligibility is confirmed by an oncology team reading your actual tissue report, not by a family history. If you have not been told your MMR or MSI result, ask for it.

Lynch syndrome is an inherited fault in the DNA mismatch repair system. A person is born with a change in one of the genes MLH1, MSH2, MSH6 or PMS2, or in EPCAM, which switches MSH2 off. That fault raises the lifetime risk of several cancers, often at a younger age than average, and each first-degree relative has a one-in-two chance of carrying it.

Mismatch repair is the cell’s spell-check for DNA copying errors, and four proteins do most of the correcting: MLH1, MSH2, MSH6 and PMS2. In Lynch syndrome one of them is faulty in every cell of the body from birth, so uncorrected errors accumulate over a lifetime in the tissues that divide fastest — the lining of the bowel and of the uterus above all.

It is inherited in an autosomal dominant pattern, so one altered copy is enough. The one-in-two figure applies to each parent, each brother and sister, and each child independently — it is not a quota used up because one sibling already tested positive. Older reports call the condition hereditary non-polyposis colorectal cancer, or HNPCC. It is the same thing.

Risk varies widely by gene and by sex — highest with MLH1 and MSH2, lower with MSH6 and PMS2. That is why NCCN surveillance guidance is written gene by gene rather than as one figure for everyone. What screening each of these cancers calls for is set out further down this page.

Because a broken repair system leaves the tumour covered in abnormal proteins. When mismatch repair is missing, DNA copying errors accumulate unchecked. The tumour ends up producing a very large number of proteins the body does not recognise. Those abnormal proteins are what make the tumour visible to immune cells, and checkpoint inhibitor immunotherapy works by taking the brakes off that recognition.

A microsatellite stable tumour has a working spell-check. It carries far fewer abnormal proteins, so immune cells largely do not see it as foreign, and releasing the brakes achieves very little when there is nothing to look at. This is biology, not effort, access or money.

For the group that is MSI-High, the benefit described in the literature is worth naming precisely. Published trial data summarised in NCCN and ESMO guidance describe objective response rates broadly in the 40 to 45 percent range for MSI-High advanced colorectal cancer treated with checkpoint inhibitor immunotherapy, current as of August 2026. A response rate describes tumour shrinkage in a proportion of patients. It is not a survival figure, and it is not a prediction for any one person.

One distinction is worth holding on to: the oncologist treats the tumour result, not the inherited diagnosis. Where a tumour tests pMMR despite a strong family history, which does happen, the immunotherapy question is answered on the tumour. How that line is read is covered in MSI-High and dMMR: What These Results Mean for Immunotherapy.

Your immunotherapy eligibility does not wait on steps three and four. That question was already answered at step one, by the tumour.

Yes — and this is one of the clearest opportunities in cancer care. If an inherited variant has been confirmed in you, each parent, brother, sister and child has a one-in-two chance of carrying the same change. A relative who carries it can begin bowel screening years before a cancer would be expected to appear. A relative who does not can stop worrying.

• Start with first-degree relatives — parents, siblings and children first, then outwards from anyone who tests positive. This stepwise approach is called cascade testing.
• Their test is simpler than yours — once your exact variant is known, a relative needs only a single-site test for that one change, not a full gene panel. Laboratory charges vary, and any figure quoted is indicative, as of August 2026.
• A negative result is a real result — a relative who does not carry the known family variant returns to routine population screening, with no extra colonoscopies.
• Timing is usually early adulthood — testing is generally offered from the late teens or early twenties, when screening decisions start to matter. A genetic counsellor advises on younger relatives rather than testing children by default.
• Ask for a family letter — clinical genetics services write a plain-language letter naming the variant and the test to request, which you can forward to relatives instead of explaining the genetics yourself.

This is the part families most often go home without. The treatment conversation absorbs everything, the genetics conversation gets postponed, and a sibling who could have started colonoscopy at twenty-five starts at fifty like everybody else.

• Eligibility is confirmed on tissue, not on family history — where the MMR/MSI report is old, unclear, or from another centre, the slides are re-read rather than taken on trust.
• Hepatitis B and C screening is standard protocol — not a comment on your history. Immune-related side effects are sometimes treated with steroids, and a previous hepatitis infection can reactivate when the immune system is suppressed. Screening first lets the team plan monitoring or preventive antiviral treatment. More detail in Hepatitis B and C Before Immunotherapy.
• Baseline organ-function bloods are recorded — thyroid, liver, kidney and blood counts before the first cycle, so later changes can be recognised as immune-related rather than guessed at.
• Treatment runs as day care — immunotherapy is administered as day care at CION centres, so an overnight stay is not usually needed. Response-assessment PET-CT is coordinated at partner imaging centres rather than performed in-house.

• Once treatment starts, telling an immune-related bowel problem from the cancer itself is genuinely hard. Bowel Symptoms on Immunotherapy When You Already Have Bowel Cancer sets out how the two differ.
• What treatment for a GI cancer costs in India, and which schemes contribute, is set out with indicative figures in Cost of Immunotherapy for GI Cancers in India.
• The same eligibility-by-biomarker pattern turns up in breast cancer, where treatment is sometimes given before surgery. Immunotherapy Before Surgery for Triple-Negative Breast Cancer is the closest parallel.
• For how treatment is delivered, monitored and scheduled as day care, see Immunotherapy at CION Cancer Clinics.

Not sure whether the MMR/MSI test was ever done on your report? Book a free consultation and a medical oncologist will read it with you.